top of page
ABOUT
HUMAN VOICE
SCIENCE
PRESS RELEASES
MEET US
WORK WITH US
CONTACT
WE LIKE TO SHARE OUR GOOD NEWS WITH YOU AND THE WORLD. PLEASE FIND ALL OUR PRESS RELEASES HERE:
JULY 2025
JACOB FALCK HANSEN APPOINTED AS CHIEF EXECUTIVE OFFICER OF VESPER BIO
READ PRESS RELEASE
MAY 2025
VESPER BIO ACHIEVES ENROLMENT MILESTONE IN PHASE IB/IIA TRIAL OF LEAD CANDIDATE VES001 FOR FRONTOTEMPORAL DEMENTIA.
READ PRESS RELEASE
JANUARY 2025
VESPER BIO INITIATES PHASE IB/IIA PROOF OF CONCEPT STUDY OF VES001 IN ASYMPTOMATIC PATIENTS WITH GENE MUTATIONS THAT CAUSE FRONTOTEMPORAL DEMENTIA (FTD).
READ PRESS RELEASE
SEPTEMBER 2024
VESPER BIO ANNOUNCES SUCCESSFUL PHASE I STUDY FOR POTENTIALLY DISEASE-MODIFYING TREATMENT FOR FRONTOTEMPORAL DEMENTIA.
READ PRESS RELEASE
MAY 2024
VESPER BIO ANNOUNCES COMPLETION OF SINGLE ASCENDING DOSE STAGE IN TRIAL OF ITS LEAD CANDIDATE VES001.
READ PRESS RELEASE
JANUARY 2024
VESPER BIO AWARDED GRANT BY THE MICHAEL J. FOX FOUNDATION TO ASSESS SORTILIN INHIBITORS IN THE TREATMENT OF PARKINSON’S DISEASE.
READ PRESS RELEASE
DECEMBER 2023
PHASE I STUDY UNDERWAY AS FIRST VOLUNTEER DOSED WITH VES001, A FIRST-IN-CLASS ORAL TREATMENT FOR FRONTOTEMPORAL DEMENTIA.
READ PRESS RELEASE
bottom of page
